CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia

Affiliations

¹ Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre Bénite 69495, France. Electronic address: xavier.thomas@chu-lyon.fr.
² Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre Bénite 69495, France.

Comment

Xavier Thomas et al. Lancet Haematol. 2021 Jul.

. 2021 Jul;8(7):e468-e469.

doi: 10.1016/S2352-3026(21)00145-9.

¹ Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre Bénite 69495, France. Electronic address: xavier.thomas@chu-lyon.fr.
² Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre Bénite 69495, France.

No abstract available

Conflict of interest statement

We declare no competing interests.

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. Lancet JE, et al. Lancet Haematol. 2021 Jul;8(7):e481-e491. doi: 10.1016/S2352-3026(21)00134-4. Lancet Haematol. 2021. PMID: 34171279 Clinical Trial.